Numinus Wellness Inc. Reports Q1 2022 Results
Ended the quarter with a strong cash position of $53.9 million Revenues grew 245% year-over-year to $0.8 million for the quarter Generated gross profit of $50,965 during the quarter, representing a 6.5% gross margin Well-positioned to offer psychedelic-assisted psychotherapy ... [Read]
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus has received approvals from Health Canada and the Institutional Ethics Review Board VANCOUVER, BC, Jan. 19, 2022 – Numinus Wellness Inc. (TSXV:NUMI) (“Numinus” or the “Company”), a leader in psychedelics-focused mental healthcare, is pleased ... [Read]
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product
The trial evaluates Numinus’ first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 – Numinus Wellness Inc. (TSXV:NUMI)(“Numinus“), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally ... [Read]
Numinus to Host Q1 2022 Results Conference Call on January 13, 2022
VANCOUVER, BC, Jan. 5, 2022 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”) (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for ... [Read]
Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines
Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis VANCOUVER, BC, Dec. 22, 2021 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”), a ... [Read]
Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021
Numinus will ring the TSX opening bell to celebrate this milestone VANCOUVER, BC, Dec. 14, 2021 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, ... [Read]
Numinus Wellness Inc. Reports Q4 and Year End 2021 Results
Ended the year with a strong cash position of $59.2 million Revenues grew 81% year-over-year to $0.5 million for Q4 2021 Revenues grew 72% year-over-year to $1.5 million for FY 2021 Gross profit of $31,818 for Q4 2021 Completed the acquisition ... [Read]
Numinus Announces Departure of Stacey Wallin
VANCOUVER, BC, Nov. 25, 2021 /PRNewswire/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today following the conclusion of several weeks of discussions ... [Read]
Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021
VANCOUVER, BC, Nov. 22, 2021 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August ... [Read]
Numinus to Begin Trading on the OTC Under Symbol NUMIF
VANCOUVER, BC, Nov. 19, 2021 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its ticker symbol on the OTC ... [Read]